Filtered By:
Cancer: Cancer
Therapy: Gene Therapy

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 250 results found since Jan 2013.

Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells
maagacli
Source: Cancer Gene Therapy - June 6, 2014 Category: Cancer & Oncology Authors: M KoldehoffD W BeelenA H Elmaagacli Source Type: research

Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery.
Abstract Targeted delivery of therapeutic genes to the tumor site is critical for successful and safe cancer gene therapy. The arginine grafted bio-reducible poly (cystamine bisacrylamide-diaminohexane, CBA-DAH) polymer (ABP) conjugated poly (amido amine) (PAMAM), PAM-ABP (PA) was designed previously as an efficient gene delivery carrier. To achieve high efficacy in cancer selective delivery, we developed the tumor targeting bio-reducible polymer, PA-PEG1k-RGD, by conjugating cyclic RGDfC (RGD) peptides, which bind αvβ3/5 integrins, to the PAM-ABP using polyethylene glycol (PEG, 1 kDa) as a spacer. Physical cha...
Source: Biomaterials - May 31, 2014 Category: Materials Science Authors: Kim HA, Nam K, Kim SW Tags: Biomaterials Source Type: research

Knockdown of ribosomal protein L39 by RNA interference inhibits the growth of human pancreatic cancer cells in vitro and in vivo.
Abstract Pancreatic cancer remains a major unsolved health problem lacking a potent therapeutic option. Our previous studies showed that the ribosomal protein L39 (RPL39) gene was up-regulated after long-term silencing of oncogenic KRAS in pancreatic cancer PANC-1 cells, which indicated that RPL39 may be important for pancreatic cancer development and survival. In the current study, small interfering RNA (siRNA) targeting of the RPL39 gene was performed to determine the effects of the RPL39 gene on growth of pancreatic cancer PANC-1 and BxPC-3 cells in vitro and in vivo. Results from in vitro experiments showed th...
Source: Biotechnology Journal - May 1, 2014 Category: Biotechnology Authors: Li CO, Chen D, Luo M, Ge M, Zhu J Tags: Biotechnol J Source Type: research

Biscarbamate cross-linked low molecular weight Polyethylenimine polycation as an efficient intra-cellular delivery cargo for cancer therapy
Conclusions: Results in this study suggested that PEI-Bu polycation might provide a promising solution for siRNA delivery and had the potential in anti-tumor gene therapy.
Source: Journal of Nanobiotechnology - April 6, 2014 Category: Nanotechnology Authors: Xuemei GeJia FengShun ChenCan ZhangYuanming OuyangZhenguo LiuWeien Yuan Source Type: research

Mp34-06 gmcsf gene therapy and sirna targeting cox-2 in a murine model of bladder cancer
Source: The Journal of Urology - April 1, 2014 Category: Urology & Nephrology Authors: Sin Mun Tham, Kesavan Esuvaranathan, Ratha Mahendran Tags: Bladder Cancer: Basic Research III (MP34) Source Type: research

Multifunctional nanocarrier based on clay nanotubes for efficient intracellular siRNA delivery and gene silencing
In this study, a novel multifunctional nanocarrier based on functionalized halloysite nanotubes (f-HNTs) has been developed via electrostatic layer-by-layer assembling approach for loading and intracellular delivery of therapeutic antisurvivin siRNA and simultaneously tracking their intracellular transport, in which PEI-modified HNTs are used as gene vector, antisurvivin siRNA as gene therapeutic agent, and mercaptoacetic acid-capped CdSe quantum dots as fluorescent labeling probes. The successful assembly of the f-HNTs-siRNA complexes was systematically characterized by transmission electron microscopy (TEM), UV–vis...
Source: Journal of Biomaterials Applications - March 25, 2014 Category: Materials Science Authors: Wu, H., Shi, Y., Huang, C., Zhang, Y., Wu, J., Shen, H., Jia, N. Tags: Articles Source Type: research

The inhibitory effect of a new scFv/tP protein as siRNA delivery system to target hWAPL in cervical carcinoma.
Abstract Targeted immunotherapy has become a popular research topic in cancer. The development and metastasis of cervical carcinoma are closely related to epidermal growth factor (EGF) and EGF-1 receptor (EGFR). We successfully constructed a single-chain human anti-EGFR antibody (scFv) and truncated protamine (tP) fusion protein (scFV/tP) expression vector using overlap extension PCR. Enzyme-linked immunosorbent assay and gel shift assay showed that the fusion protein retained the DNA and antigen-binding activity of the original antibody. Using the non-viral scFv/tP vector as a delivery tool, small interfering RNA...
Source: Molecular and Cellular Biochemistry - February 25, 2014 Category: Biochemistry Authors: Zhang H, Mao Y, Zhang F, Ye C, Tong H, Su Y, Zhu J Tags: Mol Cell Biochem Source Type: research

Superparamagnetic iron oxide nanoparticles mediated 131I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice
Conclusions: EMF-guided 131I-hVEGF siRNA/SilenceMag exhibited an antitumor effect. The synergic therapy of 131I-hVEGF siRNA/SilenceMag might be a promising future treatment option against HCC with the dual functional properties of tumor therapy and imaging.
Source: BMC Cancer - February 21, 2014 Category: Cancer & Oncology Authors: Jing ChenShu ZhuLiangqian TongJiansha LiFei ChenYunfeng HanMing ZhaoWei Xiong Source Type: research

Effects of stable ANO1 overexpression on biological behaviors of human laryngeal squamous cell carcinoma Hep-2 cells in vitro.
CONCLUSION: ANO1 overexpression does not significantly affect the proliferation of cancer cells, but can enhance the migration ability of head and neck squamous cell carcinoma, suggesting the value of ANO1 as a new gene therapy target for head and neck squamous cell carcinoma. PMID: 24589607 [PubMed - in process]
Source: Journal of Southern Medical University - February 20, 2014 Category: Universities & Medical Training Authors: Li YD, Zhang JS, Yang K, Zhang FJ, Chen R, Chen D Tags: Nan Fang Yi Ke Da Xue Xue Bao Source Type: research

FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer
Conclusions: These results suggest that FOXA1 promotes cell proliferation by AR and activates Notch pathway. It indicated that FOXA1 and AR may serve as potential gene therapy in EC.
Source: BMC Cancer - February 11, 2014 Category: Cancer & Oncology Authors: Meiting QiuWei BaoJingyun WangTingting YangXiaoying HeYun LiaoXiaoping Wan Source Type: research

Silencing of Glucose Transporter Protein-1 by RNA Interference Inhibits Human Osteosarcoma Mg63 Cells Growth in vivo.
Abstract While knock-down of glucose transporter protein 1 (GLUT-1) inhibited various human cancer cell growth in vitro and in vivo, including osteosarcoma cell growth in vitro, there has been no report on whether knock-down of GLUT-1 by siRNA may inhibit osteosarcoma cell growth in vivo. We hypothesized that siRNA may inhibit osteosarcoma cell growth in vivo. We introduced siRNA-GLUT-1 by lentivirus into MG63 osteosarcoma cells which were xenograted into nude mice. Immunohistochemical staining, Western blot and reverse transcriptase quantitative (RT-qPCR) were used to determine GLUT-1 protein and mRNA expression ...
Source: Technology in Cancer Research and Treatment - February 3, 2014 Category: Cancer & Oncology Authors: Jian F, Yuan F, Jiong M, Zhu XZ, Yu GR, Lu DD Tags: Technol Cancer Res Treat Source Type: research

Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells.
In this study, we constructed novel oncolytic adenoviruses in which the Ki67 core promoter drove expression of the E1A gene. These adenoviruses were equipped with either a Ki67 small interfering RNA (siRNA), a human telomerase reverse transcriptase (hTERT) siRNA or a double siRNA targeting Ki67 and hTERT. We identified the antitumor activities of oncolytic adenoviruses in 3 renal cancer cell lines, human normal renal tube cell HK-2 and also in nude mice bearing KETR-3-xenografted tumors. Our results showed that these oncolytic adenoviruses, especially Ki67-ZXC2-double siRNA, could effectively induce silencing of the Ki67 a...
Source: Virus Research - January 21, 2014 Category: Virology Authors: Fang L, Cheng Q, Li W, Liu J, Li L, Xu K, Zheng J Tags: Virus Res Source Type: research

Murine Double Minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo
Abstract: Prostate cancer (PCa) often shows either mutations of the p53 gene or inactivation of the P53 protein. The latter may be due to up-regulation of mouse double minute 2 homologue (MDM2), which functions both as an E3 ubiquitin ligase to degrade P53 protein via the proteasome and an inhibitor of P53 transcriptional activation. Zinc plays a crucial role in stabilizing the P53 DNA binding domain, but PCa cells often lack the ability to accumulate sufficient zinc. In the present study, we explore the optimal approach to retention of P53 function. To restore the defective P53 pathway in PCa, we have explored a combined ...
Source: European Journal of Cancer - January 21, 2014 Category: Cancer & Oncology Authors: Junlian Gu, Bo Wang, Yanan Liu, Lingzhi Zhong, Yufeng Tang, Hua Guo, Tao Jiang, Liwei Wang, Yang Li, Lu Cai Tags: Basic science and preclinical research Source Type: research

Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity
Signal transducer and activator of transcription 3 (STAT3) is an oncogene and immune checkpoint commonly activated in cancer cells and in tumor-associated immune cells. We previously developed an immunostimulatory strategy based on targeted Stat3 silencing in Toll-like receptor 9 (TLR9)-positive hematopoietic cells using CpG-small interfering RNA (siRNA) conjugates. Here, we assessed the therapeutic effect of systemic STAT3 blocking/TLR9 triggering in disseminated acute myeloid leukemia (AML). We used mouse Cbfb-MYH11/Mpl-induced leukemia model, which mimics human inv(16) AML. Our results demonstrate that intravenously del...
Source: Blood - January 2, 2014 Category: Hematology Authors: Hossain, D. M. S., Dos Santos, C., Zhang, Q., Kozlowska, A., Liu, H., Gao, C., Moreira, D., Swiderski, P., Jozwiak, A., Kline, J., Forman, S., Bhatia, R., Kuo, Y.-H., Kortylewski, M. Tags: Plenary Papers, Myeloid Neoplasia, Gene Therapy Source Type: research

Murine double minute 2 siRNA and wild-type p53 gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro and in vivo
Highlights: Abstract: SKOV3/DDP cells urgently require an efficient therapy to improve drug resistance. Here we show a critical role for cisplatin combined with gene therapy, using transfection of a p53 gene/MDM2-siRNA plasmid, in improving cisplatin sensitivity of SKOV3/DDP cells with a strong inhibition of tumor cell growth in vitro and in vivo. The effects may be associated with enhancement of intracellular platinum accumulation via decreased MDR1/P-gp and improvement of apoptotic resistance via increased P53, PUMA and NOXA expression. The combined therapy may efficiently inhibit cell invasion and migration via deceased...
Source: Cancer Letters - December 2, 2013 Category: Cancer & Oncology Authors: Junlian Gu, Yufeng Tang, Yanan Liu, Hua Guo, Yue Wang, Lu Cai, Yang Li, Bo Wang Tags: Research Articles Source Type: research